21 results
P
patients with acute spinal cord injury
I/C
prophylactic medication for HO, placebo
O
incidence of HO
P
non-ICU patients
I/C
acid-suppressive medications, placebos (gastric mucosa protectants), H2-receptor antagonists, proton pump inhibitors (PPIs)
O
occurrence of SU bleeding, adverse drug events (ADEs)
P
fractures involving the posterior malleolus (PM) of the ankle
I/C
cannulated screws versus plate with screw fixation, no statistically significant difference in the development of postoperative ankle osteoarthritis and functional outcomes
O
no significant difference in the development of postoperative ankle osteoarthritis and functional outcomes
P
soggetti esposti professionalmente a glifosato
I/C
esposizione professionale a glifosato, soggetti non esposti a glifosato
O
rischio di linfoma non Hodgkin (NHL) e mieloma multiplo (MM)
P
older adults without cognitive impairment
I/C
anticholinergic medications, cognitive decline or dementia
O
risk of cognitive decline or dementia
P
chronic liver disease, hepatitis C, hepatitis B
I/C
antiviral therapy, hepatitis B, hepatitis C
O
health utility scores
P
patients with dry eye
I/C
autologous serum treatment, artificial tear drops
O
adverse effects, quality of life, severity of the pathology, pain, corneal epitheliopathy grade
P
patients with knee osteoarthritis
I/C
offloader knee braces, use of offloader knee braces vs. no use
O
physical function, pain, quality of life, adverse events
P
adults
I/C
heterologous immunization schedules, homologous immunization schedules, different heterologous and homologous regimens
O
neutralizing antibodies against the original strain, serious adverse events (SAEs)
P
cancer patients
I/C
direct-acting oral anticoagulants, low molecular weight heparin
O
major bleeding, thromboembolic disease, quality of life, mortality